Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

(2021) Obbina Abani et al.   LANCET

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19

(2021) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19

(2021) Kun Li et al.   mBio

Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

(2020) Ning Tang et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19

(2020) Markus Hoffmann et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy

(2020) Sukbin Jang et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

(2020) Songping Cui et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Thromboelastography Profiles of Critically Ill Patients With Coronavirus Disease 2019

(2020) Eugene Yuriditsky et al.   CRITICAL CARE MEDICINE

Comparative analysis of antiviral efficacy of FDA‐approved drugs against SARS‐CoV‐2 in human lung cells

(2020) Meehyun Ko et al.   JOURNAL OF MEDICAL VIROLOGY

Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications

(2020) Divij Mathew et al.   SCIENCE

The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner

(2020) Mizuki Yamamoto et al.   Viruses-Basel

Coagulation abnormalities and thrombosis in patients with COVID-19

(2020) Marcel Levi et al.   Lancet Haematology

Comprehensive mapping of immune perturbations associated with severe COVID-19

(2020) Leticia Kuri-Cervantes et al.   Science Immunology

Functional testing of tranexamic acid effects in patients undergoing elective orthopaedic surgery

(2020) Philipp Groene et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

The Impact of Carboxylesterases in Drug Metabolism and Pharmacokinetics

(2018) Li Di   CURRENT DRUG METABOLISM

Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay

(2016) Mizuki Yamamoto et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk

(2015) Ji-Young Choi et al.   MEDICINE

TEG and ROTEM: Technology and clinical applications

(2013) David Whiting et al.   AMERICAN JOURNAL OF HEMATOLOGY

A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study

(2008) Yan-guang Cao et al.   ANALYTICAL AND BIOANALYTICAL CHEMISTRY